NCT05988372
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
- Minor Interventions: Albumin-paclitaxel + Gemcitabine (Drug), Sulfatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug) to Albumin-paclitaxel + Gemcitabine (Drug), Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug)
- Study description revised
- Study title revised
Notable Start date: Aug 30, 2023 to Oct 23, 2023v3 Show 8 more changesShow less
- Enrollment target: 42 to 50
- Primary completion date: Aug 30, 2023 to Oct 23, 2023
- Study completion date: Aug 30, 2026 to Oct 23, 2026
- Interventions: Albumin-paclitaxel (Drug), Gemcitabine (Drug), Serplulimab (Drug), Sulfatinib (Drug) to Albumin-paclitaxel + Gemcitabine (Drug), Sulfatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug)
- Secondary endpoints: 6 to 7
- Study description expanded, about 178 words
- Study arms: 1 to 2
- Study title shortened, about 1 word
- Minor Study title expanded, about 5 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
R0 Surgical Resection Rate
Timeframe: Up to 2 years
Secondary (7)
Surgical conversion rate
Objective response rate (ORR)
Deepness of response (DpR)
Progression-Free Survival (PFS)
Disease-free survival (DFS)
Show 2 moreShow less
Over Survival (OS)
Quality of Life (QOL)
Arms and interventions
Surufatinib + Serplulimab+Albumin-paclitaxel + GemcitabineExperimental
enrolled, eligible patients receive Surufatinib, Serplulimab, Gemcitabine and Albumin-paclitaxel
Albumin-paclitaxel + GemcitabineExperimental
enrolled, eligible patients receive Gemcitabine and Albumin-paclitaxel
Drugs: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine, Albumin-paclitaxel + Gemcitabine
Sites
1 site in 1 country
- First Affiliated Hospital, Sun Yat-Sen UniversityGuangzhou, Guangdong, China